Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
RESEARCH TRIANGLE PARK, N.C. - Simulations Plus, Inc. (NASDAQ:SLP) announced it has rescheduled the release of its third fiscal quarter financial results from July 2 to July 14, 2025, with a conference call set for 5 p.m. Eastern Time on the same day. The company, currently valued at $363 million, has maintained strong financial health metrics according to InvestingPro data.
The biosimulation and cheminformatics provider reaffirmed its preliminary revenue expectations for the third quarter, projecting between $19 million and $20 million. The company also maintained its full-year fiscal 2025 revenue guidance of $76 million to $80 million, which was previously announced on June 11. This guidance aligns with the company’s historical growth trajectory, having achieved a 21.5% revenue increase over the last twelve months to $78.6 million.
Simulations Plus noted that since transitioning from a large accelerated filer to a non-accelerated filer, it is utilizing the full time allowed by regulations before releasing its quarterly results. The company expects to file its Quarterly Report on Form 10-Q by July 15, 2025, the SEC filing deadline. The company maintains a strong financial position with a current ratio of 4.37, indicating ample liquidity to meet short-term obligations.
The preliminary financial results remain subject to adjustment during the finalization of quarter-end financial procedures. The company cautioned that actual results could differ from these preliminary estimates. Recent market activity has seen the stock decline 30.7% over the past week, trading near its 52-week low of $18.25. InvestingPro analysis indicates the stock may be undervalued at current levels, with 12 additional ProTips available for subscribers.
Simulations Plus provides software and consulting services to the biopharma industry, specializing in drug discovery and development solutions that incorporate artificial intelligence and machine learning technologies. The company maintains healthy profit margins with a gross profit margin of 55.3% and operates with minimal debt, positioning it well in the competitive software solutions market.
The information in this article is based on a press release statement from the company.
In other recent news, Simulations Plus has reported a reduction in its fiscal 2025 revenue guidance, with expectations now set between $76 million and $80 million. This revision follows preliminary third-quarter results indicating a 14% decline in revenue compared to analyst expectations. Market uncertainties affecting pharmaceutical and biotech clients have been cited as significant factors contributing to this downward adjustment. In response to these challenges, the company announced a strategic reorganization, shifting from a business unit structure to a functionally driven model, and implementing leadership changes, including the appointment of John DiBella as Chief Revenue Officer. Stephens lowered its price target for Simulations Plus to $28 from $42, maintaining an Overweight rating, while JMP Securities kept its Market Perform rating despite reducing its financial forecasts. Simulations Plus also launched DILIsym 11, a new version of its quantitative systems toxicology software, featuring a pediatric focus to enhance drug safety predictions for children. These developments reflect the company’s ongoing efforts to adapt to market conditions and maintain its competitive edge in the pharmaceutical software industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.